143 related articles for article (PubMed ID: 17585052)
1. Notch1 co-opts lymphoid enhancer factor 1 for survival of murine T-cell lymphomas.
Spaulding C; Reschly EJ; Zagort DE; Yashiro-Ohtani Y; Beverly LJ; Capobianco A; Pear WS; Kee BL
Blood; 2007 Oct; 110(7):2650-8. PubMed ID: 17585052
[TBL] [Abstract][Full Text] [Related]
2. The nuclear effector of Wnt-signaling, Tcf1, functions as a T-cell-specific tumor suppressor for development of lymphomas.
Tiemessen MM; Baert MR; Schonewille T; Brugman MH; Famili F; Salvatori DC; Meijerink JP; Ozbek U; Clevers H; van Dongen JJ; Staal FJ
PLoS Biol; 2012; 10(11):e1001430. PubMed ID: 23185135
[TBL] [Abstract][Full Text] [Related]
3. The homeoprotein Dlx5 drives murine T-cell lymphomagenesis by directly transactivating Notch and upregulating Akt signaling.
Tan Y; Sementino E; Xu J; Pei J; Liu Z; Ito TK; Cai KQ; Peri S; Klein-Szanto AJ; Wiest DL; Testa JR
Oncotarget; 2017 Feb; 8(9):14941-14956. PubMed ID: 28122332
[TBL] [Abstract][Full Text] [Related]
4. Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease.
Ren M; Cowell JK
Blood; 2011 Jun; 117(25):6837-47. PubMed ID: 21527531
[TBL] [Abstract][Full Text] [Related]
5. Notch1 promotes survival of E2A-deficient T cell lymphomas through pre-T cell receptor-dependent and -independent mechanisms.
Reschly EJ; Spaulding C; Vilimas T; Graham WV; Brumbaugh RL; Aifantis I; Pear WS; Kee BL
Blood; 2006 May; 107(10):4115-21. PubMed ID: 16449526
[TBL] [Abstract][Full Text] [Related]
6. Lymphoid enhancer factor-1 mediates loading of Pax3 to a promoter harbouring lymphoid enhancer factor-1 binding sites resulting in enhancement of transcription.
Christova T; Mojtahedi G; Hamel PA
Int J Biochem Cell Biol; 2010 May; 42(5):630-40. PubMed ID: 20006729
[TBL] [Abstract][Full Text] [Related]
7. Deregulated NOTCH signaling in acute T-cell lymphoblastic leukemia/lymphoma: new insights, questions, and opportunities.
Aster JC
Int J Hematol; 2005 Nov; 82(4):295-301. PubMed ID: 16298817
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of lymphoid enhancer factor 1 inhibits colon cancer progression in vitro and in vivo.
Wang WJ; Yao Y; Jiang LL; Hu TH; Ma JQ; Liao ZJ; Yao JT; Li DF; Wang SH; Nan KJ
PLoS One; 2013; 8(10):e76596. PubMed ID: 24098538
[TBL] [Abstract][Full Text] [Related]
9. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma.
Weng AP; Millholland JM; Yashiro-Ohtani Y; Arcangeli ML; Lau A; Wai C; Del Bianco C; Rodriguez CG; Sai H; Tobias J; Li Y; Wolfe MS; Shachaf C; Felsher D; Blacklow SC; Pear WS; Aster JC
Genes Dev; 2006 Aug; 20(15):2096-109. PubMed ID: 16847353
[TBL] [Abstract][Full Text] [Related]
10. Characterization of LEF1 High Expression and Novel Mutations in Adult Acute Lymphoblastic Leukemia.
Guo X; Zhang R; Liu J; Li M; Song C; Dovat S; Li J; Ge Z
PLoS One; 2015; 10(5):e0125429. PubMed ID: 25942645
[TBL] [Abstract][Full Text] [Related]
11. The transcription factor LEF1 promotes tumorigenicity and activates the TGF-β signaling pathway in esophageal squamous cell carcinoma.
Zhao Y; Zhu J; Shi B; Wang X; Lu Q; Li C; Chen H
J Exp Clin Cancer Res; 2019 Jul; 38(1):304. PubMed ID: 31296250
[TBL] [Abstract][Full Text] [Related]
12. Growth factor independent-1 maintains Notch1-dependent transcriptional programming of lymphoid precursors.
Phelan JD; Saba I; Zeng H; Kosan C; Messer MS; Olsson HA; Fraszczak J; Hildeman DA; Aronow BJ; Möröy T; Grimes HL
PLoS Genet; 2013; 9(9):e1003713. PubMed ID: 24068942
[TBL] [Abstract][Full Text] [Related]
13. Aberrant lymphocyte enhancer-binding factor 1 expression is characteristic for sporadic Burkitt's lymphoma.
Walther N; Ulrich A; Vockerodt M; von Bonin F; Klapper W; Meyer K; Eberth S; Pukrop T; Spang R; Trümper L; Kube D
Am J Pathol; 2013 Apr; 182(4):1092-8. PubMed ID: 23375451
[TBL] [Abstract][Full Text] [Related]
14. Essential roles for ankyrin repeat and transactivation domains in induction of T-cell leukemia by notch1.
Aster JC; Xu L; Karnell FG; Patriub V; Pui JC; Pear WS
Mol Cell Biol; 2000 Oct; 20(20):7505-15. PubMed ID: 11003647
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic and Tumor Suppressor Functions for Lymphoid Enhancer Factor 1 in
Carr T; McGregor S; Dias S; Verykokakis M; Le Beau MM; Xue HH; Sigvardsson M; Bartom ET; Kee BL
Front Immunol; 2022; 13():845488. PubMed ID: 35371057
[TBL] [Abstract][Full Text] [Related]
16. The common oncogenomic program of NOTCH1 and NOTCH3 signaling in T-cell acute lymphoblastic leukemia.
Choi SH; Severson E; Pear WS; Liu XS; Aster JC; Blacklow SC
PLoS One; 2017; 12(10):e0185762. PubMed ID: 29023469
[TBL] [Abstract][Full Text] [Related]
17. Lymphoid enhancer-binding factor-1 promotes stemness and poor differentiation of hepatocellular carcinoma by directly activating the NOTCH pathway.
Fang S; Liu M; Li L; Zhang FF; Li Y; Yan Q; Cui YZ; Zhu YH; Yuan YF; Guan XY
Oncogene; 2019 May; 38(21):4061-4074. PubMed ID: 30696957
[TBL] [Abstract][Full Text] [Related]
18. The TCF-1 and LEF-1 transcription factors have cooperative and opposing roles in T cell development and malignancy.
Yu S; Zhou X; Steinke FC; Liu C; Chen SC; Zagorodna O; Jing X; Yokota Y; Meyerholz DK; Mullighan CG; Knudson CM; Zhao DM; Xue HH
Immunity; 2012 Nov; 37(5):813-26. PubMed ID: 23103132
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical Expression of Lymphoid Enhancer Binding Factor 1 in CD5-Positive Marginal Zone, Lymphoplasmacytic, and Follicular Lymphomas.
Patel N; Durkin L; Bodo J; Hsi ED
Am J Clin Pathol; 2020 Apr; 153(5):646-655. PubMed ID: 31953940
[TBL] [Abstract][Full Text] [Related]
20. The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.
Durinck K; Wallaert A; Van de Walle I; Van Loocke W; Volders PJ; Vanhauwaert S; Geerdens E; Benoit Y; Van Roy N; Poppe B; Soulier J; Cools J; Mestdagh P; Vandesompele J; Rondou P; Van Vlierberghe P; Taghon T; Speleman F
Haematologica; 2014 Dec; 99(12):1808-16. PubMed ID: 25344525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
